An injection for "double chin" reduction developed by Kythera Biopharmaceuticals Inc cleared the first hurdle toward approval as U.S. Food and Drug Administration staff concluded the drug's benefits outweighed its risks.
Kythera's stock jumped as much as 25 percent as investors bet on what could be the first approved drug in the United States to reduce localized fat deposits.
22:31 Making America great again apparently includes Cold War-era nuclear dominance17
16:51 Mexico to extradite cocaine cartel member 'El Gordo' to U.S16
19:44 Shadow president or mere shadow? In Europe, Pence seeks to reassure allies unnerved by Trump14
00:02 Omar Abdel Rahman, imprisoned ‘blind sheikh’ linked to terrorist efforts, dies at 7822